

Ovarian Cancer: Identifying and Managing Familial and Genetic Risk Committee meeting 10

Date: 16/03/2023

Location: Virtually via Zoom

Minutes: Confirmed

Committee members present:		
Alison Cameron (Chair)		(Present for notes 1 – 8)
Ranjit Manchanda (Topic Advisor)		(Present for notes 1 – 5)
Victoria Barber		(Present for notes 1 – 8)
Adam Brentnall		(Present for notes 1 – 8)
Rebecca Bowen		(Present for notes 1 – 8)
Gareth Evans		(Present for notes 1 – 5)
Judith Hayward		(Present for notes 1 – 6)
Davina Moses		(Present for notes 1 – 8)
Fiona Robb		(Present for notes 1 – 8)
Adam Rosenthal		(Present for notes 1 – 8)
Mark Davies		(Present for notes 1 – 8)
Kevin Monahan		(Present for notes 1 – 8)
Britta Stordal		(Present for notes 1 – 8)
Lucy Side		(Present for notes 1 – 8)
Joanne Stanford		(Present for notes 1 – 8)
Vishakha Tripathi		(Present for notes 1 – 6)

In attendance:		
Katharina Dworzynski	Guideline Lead	(Present for notes 1 – 8)
Hayley Shaw	Project Manager	(Present for notes 1 – 8)
Nathan Bromham	Senior Systematic Reviewer	(Present for notes 1 – 8)
Laura Berg	Systematic Reviewer	(Present for notes 1 – 8)
Steve Pilling	Clinical Advisor	(Present for notes 1 – 4)
Suhayl Kassam	Systematic Reviewer	(Present for notes 1 – 8)
Eric Slade	Senior Health Economist	(Present for notes 1 – 8)
Sarah Palombella	Senior Medical Editor	(Present for notes 1 – 8)
Expert witness attendance		

Xia Wei, PhD student – London School of Hygiene and Tropical Medicine	Present for notes 1 – 4
---	-------------------------

Apologies:	
Melanie Davies	Committee member
Glenn McCluggage	Committee member
Tracie Miles	Committee member
Emma Clegg	Information Scientist
Nick O’Callaghan-Staples	Guideline Commissioning Manager
Tara Chernick	Adoption and Implementation Manager
Adam Storrow	Resource Impact Lead
Neil Ryan	Clinical Fellow

1. Welcome, housekeeping, aims of the day and apologies
<p>The Chair welcomed the committee members and attendees to the 10th meeting on Ovarian Cancer: Identifying and Managing Familial and Genetic Risk.</p> <p>The Chair informed the committee that apologies had been received. These are noted above.</p> <p>The Chair outlined the meeting objectives.</p>
2. Confirmation of matter under discussion, and declarations of interest
<p>The Chair asked everyone to verbally declare any interests that have risen since the last meeting. No new interests were declared. Ranjit Manchanda and Gareth Evans were present for the morning presentations but were excluded from the afternoon discussions related to topic 5.1 due to a conflict arising from previously declared interests.</p>
3. Minutes of the last meeting
<p>The Chair asked the committee to confirm the minutes of the last meeting, and the committee confirmed no changes were required.</p>
4. Morning presentations
<p>The Chair introduced Laura Berg, Systematic Reviewer, Eric Slade, Senior Health Economist and Adam Rosenthal, 8.1 Topic Group Lead who presented on evidence review 8.1: ‘How effective is risk-reducing surgery for women at increased risk of familial ovarian cancer (also considering risk threshold, age and extent and types of</p>

surgery)?

Eric Slade, Senior Health Economist, gave an update on the economics work for Topic 4 including model assumptions and parameter inputs.

Katharina Dworzynski, Guideline Lead, gave a presentation on algorithm preference sensitive decision points, which included examples from other guidelines.

5. Lay member forum

Lay members were given the opportunity to reflect and make any suggestions or comments to the other committee members.

6. Afternoon presentations

The Chair introduced Suhayl Kassam, Systematic reviewer, and Britta Stordal, 5.1 Topic Group Lead, who presented evidence review question 5.1: 'Which genes should be included in a gene panel when testing for pathogenic variants that increase the risk of familial ovarian cancer?'

7. Questions and discussion

The committee discussed:

- Clinical evidence and economic evidence for 8.1. They drafted recommendations using topic group suggestions as a starting point and took into account equality considerations.
- Economic update for Topic 4
- Algorithm/ preference sensitive decision points.
- Clinical evidence for review question 5.1 They drafted recommendations using topic group suggestions as a starting point and took into account equality considerations.

8. Any other business and summary of actions

Katharina Dworzynski summarised the actions and confirmed the topics for the next meeting.

No other business was discussed.

The Chair closed the meeting at 16:30.

Date of next meeting: 05/05/2023

Location of next meeting: Via Zoom.